transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2010-0-2-5-9transplantologiya-276Research ArticleОБЗОРНЫЕ СТАТЬИ И ЛЕКЦИИREVIEW ARTICLES AND LECTURESБактериальные и грибковые инфекционные осложнения ближайшего и раннего периода трансплантацииBacterial and fungal infectious complications in the immediate and early periods of transplantationКурмуковИ. А.KurmukovI. A.

Илдар Анварович Курмуков

i_a_kurmukov@list.ruГУ РОНЦ им. Н.Н. Блохина РАМНРоссияN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesRussian Federation2010170820180259Copyright © Курмуков И.А., 20182018Курмуков И.А.Kurmukov I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/276

В обзоре представлены данные об изменении спектра бактериальных и грибковых инфекционных осложнений раннего посттрансплантационного периода, происходящем в последнее время. Приведено обсуждение некоторых причин этого изменения. Появление полирезистентных штаммов возбудителей инфекционных осложнений требует проведения эпидемиологических исследований спектра возбудителей нозокомиальных инфекций в конкретных центрах трансплантации органов и медицинских учреждениях, в которых находятся потенциальные доноры органов. Перитрансплантационная антибиотикопрофилактика и эмпирическая антибиотикотерапия должны основываться либо на результатах таких исследований, либо на комбинированном применении антибиотиков, «перекрывающих» спектр наиболее опасных возбудителей.

The review presents data on the recent change in the spectrum of bacterial and fungal infectious complications in the early posttransplantation period. It discusses some reasons for this change. The emergence of multidrug-resistant strains of infectious complications requires epidemiological studies of the spectrum of nosocomial pathogens at the specific organ transplant centers and health care facilities where potential organ donors are present. Peritransplantation antibiotic prophylaxis and empiric antibiotic therapy should be based on either the results of these studies or the combined use of antibiotics that overlap the spectrum of the most dangerous causative agents.

аллогенная трансплантацияинфекционные осложненияполирезистентные штаммыallotransplantationinfectious complicationsmultidrug-resistant strainsReferencesCandel F.J., Grima E., Matesanz M. et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc 2005;37:4097–9.Candel F.J., Grima E., Matesanz M. et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc 2005;37:4097–9.Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601–14.Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601–14.Danzinger-Isakov L., Kumar D.; AST infectious diseases community of practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transpl 2009;9(Suppl 4):258–62.Danzinger-Isakov L., Kumar D.; AST infectious diseases community of practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transpl 2009;9(Suppl 4):258–62.Kotloff R.M., Vivek N.A., Crawford S.W. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004;170:22–48; 357:2601–14.Kotloff R.M., Vivek N.A., Crawford S.W. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004;170:22–48; 357:2601–14.National Nosocomial Infections Surveillance (NNIS). System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–85.National Nosocomial Infections Surveillance (NNIS). System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–85.Parasuraman R., Samarapungavan D., Venkat K.K. Updated principles and clinical caveats in the management of infection in renal transplant recipients. Transpl Rev 2010;24:43–51.Parasuraman R., Samarapungavan D., Venkat K.K. Updated principles and clinical caveats in the management of infection in renal transplant recipients. Transpl Rev 2010;24:43–51.Mueller N.J., Weisser M., Fehr T. et al. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transpl Infect Dis 2010;12:54–9.Mueller N.J., Weisser M., Fehr T. et al. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transpl Infect Dis 2010;12:54–9.Sole A., Salavert M. Fungal infections after lung transplantation. Transpl Rev 2008;22:89–104.Sole A., Salavert M. Fungal infections after lung transplantation. Transpl Rev 2008;22:89–104.Minari A., Husni R., Avery R.K. et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002;4(4):195–200.Minari A., Husni R., Avery R.K. et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002;4(4):195–200.Neofytos D., Fishman J.A., Horn D. et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010;12:220–9.Neofytos D., Fishman J.A., Horn D. et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010;12:220–9.Singh N., Wagener M.M., Obman A. et al. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004;10:844–9.Singh N., Wagener M.M., Obman A. et al. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004;10:844–9.Candel F.J., Grima E., Matesanz M. et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc 2005;37:4097–9.Candel F.J., Grima E., Matesanz M. et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc 2005;37:4097–9.Shi S.H., Kong H.S., Xu J. et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009;11:405–12.Shi S.H., Kong H.S., Xu J. et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009;11:405–12.Methicillin (oxacillin)-resistant staphylococcus aureus (MRSA) among ICU patients. Centers for Disease Control and Prevention, 1995–2004.Methicillin (oxacillin)-resistant staphylococcus aureus (MRSA) among ICU patients. Centers for Disease Control and Prevention, 1995–2004.Cetinkaya Y., Falk P., Mayhall C.G. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686–707.Cetinkaya Y., Falk P., Mayhall C.G. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686–707.Boisivon A., Thibault M., Leclercq R. et al. Colonization by vancomycin-resistant enterococci of the intestinal tract of patients in intensive care units from French general hospitals. Clin Microbiol Infect 1997;3:175–9.Boisivon A., Thibault M., Leclercq R. et al. Colonization by vancomycin-resistant enterococci of the intestinal tract of patients in intensive care units from French general hospitals. Clin Microbiol Infect 1997;3:175–9.Metallidis S., Chatzidimitriou M., Tsona A. et al. Vancomycin-resistant enterococci, colonizing the intestinal tract of patients in a university hospital in Greece. Braz J Infect Dis 2006;10:179–84.Metallidis S., Chatzidimitriou M., Tsona A. et al. Vancomycin-resistant enterococci, colonizing the intestinal tract of patients in a university hospital in Greece. Braz J Infect Dis 2006;10:179–84.Hautemaniere A., Hunter P.R., Diguio N. et al. A prospective study of the impact of colonization following hospital admission by glycopeptide-resistant Enterococci on mortality during a hospital outbreak. Am J Infect Control 2009;37:746–52.Hautemaniere A., Hunter P.R., Diguio N. et al. A prospective study of the impact of colonization following hospital admission by glycopeptide-resistant Enterococci on mortality during a hospital outbreak. Am J Infect Control 2009;37:746–52.Wendt C., Wiesenthal B., Dietz E., Ruden H. Survival of vancomycinresistant and vancomycin-susceptible enterococci on dry surfaces. J Clin Microbiol 1998;36:3734–6.Wendt C., Wiesenthal B., Dietz E., Ruden H. Survival of vancomycinresistant and vancomycin-susceptible enterococci on dry surfaces. J Clin Microbiol 1998;36:3734–6.Shay D.K., Maloney S.A., Montecalvo M. et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993–1000.Shay D.K., Maloney S.A., Montecalvo M. et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993–1000.Cookson B.D., Macrae M.B., Barrett S.P. et al. Guidelines for the control of glycopeptide-resistant enterococci in hospitals. J Hosp Infect 2006;62:6–21.Cookson B.D., Macrae M.B., Barrett S.P. et al. Guidelines for the control of glycopeptide-resistant enterococci in hospitals. J Hosp Infect 2006;62:6–21.Orloff S.L., Busch A.M., Olyaei A.J. et al. Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg 1999;177:418–22.Orloff S.L., Busch A.M., Olyaei A.J. et al. Vancomycin-resistant Enterococcus in liver transplant patients. Am J Surg 1999;177:418–22.Mascini E.M., Jalink K.P., KampHopmans T.E. et al. Acquisition and duration of vancomycin-resistant enterococcal carriage in relation to strain type. J Clin Microbiol 2003;41:5377–83.Mascini E.M., Jalink K.P., KampHopmans T.E. et al. Acquisition and duration of vancomycin-resistant enterococcal carriage in relation to strain type. J Clin Microbiol 2003;41:5377–83.Hagen E.A., Lautenbach E., Olthoff K., Blumberg E.A. Low prevalence of colonization with vancomycin-resistant enterococcus in patients with awaiting liver transplantation. Am J Transplant 2003;3:902–5.Hagen E.A., Lautenbach E., Olthoff K., Blumberg E.A. Low prevalence of colonization with vancomycin-resistant enterococcus in patients with awaiting liver transplantation. Am J Transplant 2003;3:902–5.McNeil S.A., Malani P.N., Chenoweth C.E. et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006;15:195–203.McNeil S.A., Malani P.N., Chenoweth C.E. et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006;15:195–203.Avery R., Kalaycio M., Pohlman B. et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transpl 2005;35:497–9.Avery R., Kalaycio M., Pohlman B. et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transpl 2005;35:497–9.Dubberke E.R., Hollands J.M., Georgantopoulos P. et al. Vancomycinresistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transpl 2006;38:813–9.Dubberke E.R., Hollands J.M., Georgantopoulos P. et al. Vancomycinresistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transpl 2006;38:813–9.Hogan H.L., Hachem R.Y., Neuhauser M. et al. Clinical experience of linezolid in bone marrow transplanation patients. J Pharm Pract 2010; doi:10.1177/0897190009358773.Hogan H.L., Hachem R.Y., Neuhauser M. et al. Clinical experience of linezolid in bone marrow transplanation patients. J Pharm Pract 2010; doi:10.1177/0897190009358773.Canton R., Ruiz-Garbajosa P., Chaves R.L., Johnson A.P. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010;65:1126–36.Canton R., Ruiz-Garbajosa P., Chaves R.L., Johnson A.P. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010;65:1126–36.

The authors declare that there are no conflicts of interest present.